Celgene: No Surprise? It’s 10% Drop Says Different.
October 20, 2017 at 10:55 AM EDT
The drug maker's share price is plunging today after the company abandoned studies of an experimental Crohn's disease treatment, surprising investors. But analysts say that concerns have been mounting about the drug.
